A Study to Learn More About Asundexian (Also Called BAY2433334) for Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older Who Already Had Such a Stroke Due to a Blood Clot That Formed Outside the Heart and Travelled to the Brain, or Temporary Stroke-like Symptoms

Overview

About this study

The purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or temporary stroke-like symptoms when given in addition to standard antiplatelet therapy.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Participants must be ≥ 18 years of age

- Acute non-cardioembolic stroke or high-risk TIA

- Systemic or cerebrovascular atherosclerosis or acute non-lacunar infarct

Exclusion Criteria:

- Ischemic stroke ≤ 7 days before the index stroke event

- Index stroke following procedures or strokes due to other rare causes

- History of atrial fibrillation/flutter, left ventricular thrombus, mechanic valve or other cardioembolic source of stroke requiring anticoagulation

- History of atrial fibrillation / flutter, left ventricular thrombus, mechanical valve or other cardioembolic source of stroke requiring anticoagulation

- Previous (within 30 days of randomization or 5 half-lives of the investigational drug, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s). Registries and observational studies are allowed.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/18/24. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alejandro Rabinstein, M.D.

Open for enrollment

Contact information:

Cameron Hunter

(507) 422-0406

Hunter.Cameron@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20559174

Mayo Clinic Footer